Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.

Cancer - 15 Jan 2012

Thon Niklas, Eigenbrod Sabina, Kreth Simone, Lutz Juergen, Tonn Joerg-Christian, Kretzschmar Hans, Peraud Aurelia, Kreth Friedrich-Wilhelm

Abstract excerpt

BACKGROUND: The favorable prognostic impact of mutations in the IDH1 gene is well documented for malignant gliomas; its influence on World Health Organization (WHO) grade II astrocytomas, however, is still under debate. METHODS: A previously published database of 127 predominantly surgically treated patients harboring WHO grade II astrocytomas was revisited. Patients were screened for TP53 mutations (sequencing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Isocitrate Dehydrogenase

Share to Recurrence

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 21717448
DOI: 10.1002/cncr.26298

Genes

IDH1
MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.PMID 21717448Read ↗

Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.Semantic proximity Read ↗

Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas.Semantic proximity Read ↗

No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.Semantic proximity Read ↗

Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.Semantic proximity Read ↗

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.Semantic proximity Read ↗

IDH-mutant grade 4 astrocytoma: a comparison integrating the clinical, pathological, and survival features between primary and secondary patients.Semantic proximity Read ↗

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.Semantic proximity Read ↗

Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.Semantic proximity Read ↗

Molecular markers in low-grade gliomas: predictive or prognostic?Semantic proximity Read ↗

An Analysis of the Prognostic Value of IDH1 (Isocitrate Dehydrogenase 1) Mutation in Polish Glioma PatientsSemantic proximity Read ↗

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.Semantic proximity Read ↗

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.